Pharma majors to see muted growth in FY24: ICRA
Growth will be supported by 8-10% expansion in domestic market and 6-8% growth in US market, the agency says
Growth will be supported by 8-10% expansion in domestic market and 6-8% growth in US market, the agency says
Revenue growth will be driven by steady performance across key markets — the U.S. and India — and some recovery in growth in the European market.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
Home-grown smaller players are giving biggies a run for their money in the US generics market.
The problems faced by FDA’s investigators in India are similar to those around the world, US Food and Drug Administration spokesperson Jeremy Kahn tells Fortune India.